Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 15/20 | 0.56 |
| ▸ | CSF1R | P07333 | 3/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1275624 | 0.90 | PDE4B (0.46) | PDE4BCSF1RTHRBKCNH2ATM | |
| SCHEMBL2480491 | 0.90 | PDE4B (0.46) | PDE4BCSF1RTHRBKCNH2ATM | |
| SCHEMBL1276080 | 0.89 | PDE4B (0.78) | PDE4BCSF1RLRRK2 | |
| SCHEMBL4950077 | 0.85 | PDE4B (0.40) | PDE4BCSF1RTHRBKCNH2ATM | |
| SCHEMBL4932463 | 0.84 | LRRK2 (0.40) | PDE4BCSF1RLRRK2 | |
| SCHEMBL27670156 | 0.83 | KCNH2 (0.40) | PDE4BCSF1RTHRBKCNH2ATM | |
| SCHEMBL5590301 | 0.82 | PDE4B (0.55) | PDE4BTHRB | |
| SCHEMBL4949579 | 0.80 | THRB (0.38) | PDE4BCSF1RTHRBKCNH2ATM | |
| SCHEMBL4949972 | 0.79 | THRB (0.38) | PDE4BCSF1RTHRBKCNH2ATM | |
| SCHEMBL4607334 | 0.77 | LRRK2 (0.35) | PDE4BCSF1RTHRBLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566786-B2 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-07-28 | — | — | US | claimed |
| EP-1944305-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2008-07-16 | — | — | EP | claimed |
| EP-1633748-B1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-03-05 | — | — | EP | claimed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | claimed |
| EP-1944305-B1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LTD (GB) | 2011-10-19 | — | — | EP | disclosed |
| US-20090312325-A1 | Quinoline Derivatives As Phosphodiesterase Inhibitors | BALDWIN IAN ROBERT | 2009-12-17 | — | — | US | disclosed |
| US-7572915-B2 | 4-[(3-methylphenyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide; asthma, COPD, allergic rhinitis, or rheumatoid arthritis in a human | GLAXO GROUP LIMITED (GB) | 2009-08-11 | — | — | US | disclosed |
| US-7566786-B2 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-07-28 | — | — | US | disclosed |
| EP-1944305-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2008-07-16 | — | — | EP | disclosed |
| EP-1633748-B1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-03-05 | — | — | EP | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-20060178416-A1 | Quinoline derivatives as phosphodiesterase inhibitors | BARKER MICHAEL D | 2006-08-10 | — | — | US | disclosed |
| EP-1633748-A1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004103998-A1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178416-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | PDE4B 2/4885CSF1R 1726/4885THRB 3380/4885 |
| US-20090312325-A1 | Quinoline Derivatives As Phosphodiesterase Inhibitors | PDE3B, PDE4B, PDE4A | PDE4B 2/4885CSF1R 1726/4885THRB 3380/4885 |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | PDE4B 2/4885CSF1R 1726/4885THRB 3380/4885 |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | PDE4B 2/4885CSF1R 1726/4885THRB 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.